Genzyme Aldurazyme Patient Registry Will Evaluate AEs, Antibody Formation
Executive Summary
BioMarin/Genzyme will develop an Aldurazyme patient registry to evaluate the long-term safety and activity of the product
You may also be interested in...
TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA
Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006
TKT Hopes To Break Even In 2006 Following Hunter Syndrome Therapy BLA
Transkaryotic Therapies expects its Phase III Hunter syndrome therapy to help the company "break even" by late 2006
Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street
Millennium's multiple myeloma agent Velcade is leading the parade of oncologic therapies attracting renewed enthusiasms from investors